Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Schaeverbeke

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
Cancer Immunology, Immunotherapy : CII|March 19, 2022
Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitorsE Gefard-Gontier, R Markich, M Zysman, et al.
Annals of the Rheumatic Diseases|May 23, 2012
Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registryJ E Gottenberg, P Ravaud, A Cantagrel, et al.
Annals of the Rheumatic Diseases|June 7, 2015
Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registryJ H Salmon, J E Gottenberg, P Ravaud, et al.
The British Journal of Dermatology|October 9, 2012
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trialS Prey, K Ezzedine, A Doussau, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
Cancer Immunology, Immunotherapy : CII|March 19, 2022
Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitorsE Gefard-Gontier, R Markich, M Zysman, et al.
Annals of the Rheumatic Diseases|May 23, 2012
Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registryJ E Gottenberg, P Ravaud, A Cantagrel, et al.
Annals of the Rheumatic Diseases|June 7, 2015
Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registryJ H Salmon, J E Gottenberg, P Ravaud, et al.
The British Journal of Dermatology|October 9, 2012
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trialS Prey, K Ezzedine, A Doussau, et al.
Pageof 10